Table 6.

Characteristics of the 12 definite^c AE patients missed by the clinical algorithm.

Sex	Age (years)	Antibody	Site of antibody detection	Main clinical complaints	T0–T1 (days)	Follow-up (days)	MRI—increased FLAIR signal	EEG	CSF—Pleocyt. (cells/μl)	Tumor
Male	57	CASPR2	Serum, CSF	Cognitive symptoms, seizures	180	1,077	Left amygdala	Left temporal epileptic discharges	Yes (7)	No
Male	30	Ma2	Serum, CSF	Cognitive symptoms, psychiatric alterations, seizures	150	987	Left temporomesial	Epileptic discharges	Yes (5)	No
Female	57	Ri	Serum	Opsoclonus	56	638	Microangiopathy	Not done	Yes (64)	Cancer of unknown origin
Male	73	LGI1	Serum	Seizures, autonomic symptoms	49	1,619	Right (para-) hippocampus	Epileptic discharges	No	Prostate carcinoma
Male	65	GABA B	Serum	Seizures, facial palsy	14	350	Normal	General slowing	No	No
Female	67	LGI1	Serum, CSF	Seizures	8	920	Right amygdala and hippocampus	General slowing	Yes (11)	No
Male	40	NMDAR	Serum, CSF	Seizures, dysarthria, dysphagia	7	385	Bilateral (sub) cortical	Epileptic discharges	No	No
Male	72	CASPR2	Serum, CSF	Seizures	150	427	Right hippocampus	Regional slowing	No	No
Male	65	LGI1	Serum	Seizures	21	267	Microangiopathy	Normal	No	No
Female	70	SOX1, Amphiphysin	Serum, CSF	Seizures, hemiparesis	10	881	Normal	Epileptic discharges	No	Neuroendocrine bronchial carcinoma
Male	64	CASPR2	Serum, CSF	Seizures	1	2,321	Normal	Normal	No	No
Female	39	LGI1	Serum	Cognitive symptoms, psychiatric alterations, seizures	270	1,431	Normal	Not done	No	No